Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-masked, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants With Presbyopia

Next Previous
Trial Profile

Randomized, Double-masked, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants With Presbyopia

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Phentolamine (Primary) ; Pilocarpine (Primary)
  • Indications Presbyopia
  • Focus Registrational; Therapeutic Use
  • Acronyms VEGA 3
  • Sponsors Ocuphire Pharma

Most Recent Events

  • 26 Jun 2025 According to an Opus Genetics media release, 545 participants were enrolled at 40 investigational sites in the U.S. VEGA-3 patients will continue to be monitored for long-term safety over 48 weeks.
  • 26 Jun 2025 According to an Opus Genetics media release, along with the primary end-point the trial has also met key secondary efficacy endpoints.
  • 26 Jun 2025 According to an Opus Genetics media release, Opus Genetics management will host a webcast and conference call on 26 June 2025 at 8:00 a.m. ET to discuss the VEGA-3 results and corporate update.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top